Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis

Abstract

BACKGROUNDEyebrow loss may have substantial negative functional and social consequences.OBJECTIVEEvaluate the safety and efficacy of bimatoprost 0.03% in subjects with eyebrow hypotrichosis.METHODSThis multicenter, double-masked study randomized adult females or males with eyebrow hypotrichosis to receive bimatoprost 0.03% twice (BID) or once daily (QD) or vehicle BID for 7 months. Primary endpoint was overall eyebrow fullness at Month 7. Secondary endpoints included eyebrow fullness (mm2), darkness (intensity units), and subject satisfaction with treatment. Safety was also assessed.RESULTSAt Month 7, the proportion of subjects with improvement was significantly higher in bimatoprost groups versus vehicle (both, p < .001). Improvements occurred in both bimatoprost groups versus vehicle after Month 1 and continued through follow-up; eyebrow fullness and darkness improved as early as Months 2 and 1, respectively (both, p < .001). Greater satisfaction was reported with bimatoprost versus vehicle at Month 2 and all subsequent time points. Overall, 38.1%, 42.4%, and 35.5% of subjects in the bimatoprost BID, QD, and vehicle groups, respectively, experienced ≥1 treatment-emergent adverse event (TEAE). Most frequent TEAEs were similar across groups. No skin or iris hyperpigmentation or conjunctival hyperemia occurred.CONCLUSIONBimatoprost 0.03% BID and QD is safe, well tolerated, and effective for eyebrow hypotrichosis.

Topical Treatment of Eyebrow Hypotrichosis with Bimatoprost 0.03% Solution: Case Report and Literature Review

“…Bimatoprost was approved by the Food and Drug Administration for the treatment of eyelash hypotrichosis in 2008 [ 9 ]. The medication is a prostamide F 2α analogue; it demonstrated the side effect of eyelash growth when utilized in the treatment of glaucoma and ocular hypertension [ 2 ].…”

“…Prompted by the excellent response of eyelash growth with use of bimatoprost 0.03% solution, a small number of investigators have utilized bimatoprost to treat eyebrow hypotrichosis (Table 3 ) [ 3 - 7 , 9 ]. The studies included both women and men.…”

“…Bimatoprost was either applied once daily—like our patient—or twice daily to the eyebrows. Improvement was noted as early as eight weeks; however, maximum improvement was observed to occur between six to eight months [ 3 , 9 ]. Similar to our patient, hair growth was progressive and continued to increase as the patient maintained the topical treatment.…”

“…This condition can be idiopathic or related to an underlying disorder [ 1 ]. Bimatoprost 0.03% ophthalmic solution is a prostamide F 2α analog approved for the treatment of glaucoma and ocular hypertension that has also demonstrated efficacy in hair growth [ 2 - 9 ]. We describe a 60-year-old woman with eyebrow hypotrichosis who achieved excellent and sustained growth of her eyebrows with continual daily application of bimatoprost 0.03% solution.…”

Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis

“…In 2016, Carruthers et al performed a multicenter, randomized, double-blind study to compare the efficacy and safety of twice-daily topical bimatoprost 0.03% treatment, once-daily topical bimatoprost 0.03% treatment, and twice-daily vehicle treatment for 7 months for 357 patients with eyebrow hypotrichosis. 61 Assessment was performed using the GEyA scale and Digital Monitoring System Analysis, and subject satisfaction was determined using the nine-item Eyebrow Satisfaction Scale. The results indicated that bimatoprost 0.03% twice daily and once daily showed favorable results starting at month 2, with marked improvement at month 7, with no serious side effects and no differences in eyebrow improvements for the two drug groups regarding the treatment of eyebrow hypotrichosis.…”